PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin location, a major investment that will represent a new flagship site for customers. This is part of PCI’s global strategy to expand its clinical supply-chain network into continental Europe to complement offerings available at its UK and Ireland sites. The COE is expected to be completed in January 2021.
“With this expansion, our Berlin Clinical Center of Excellence will address the needs of European and global clients,” said Brian Keesee, vice president and general manager, Global Clinical Operations and Supply, PCI Pharma Services. “Berlin is an excellent logistical hub that will serve as a proactive solution to Brexit, ensuring there are no gaps in the supply chain and our clients conducting clinical trials in all parts of Europe continue to be served.”
The Berlin COE will include 17,000 square feet of space dedicated to primary and secondary packaging, storage of pharmaceutical and biopharmaceutical therapies at all temperature ranges, and distribution. This capacity is well positioned to service the EU-based clinical trials ecosystem, which currently has more than 38,100 active trials sites throughout the 27-member countries and is second only to the United States for such research. Of the EU countries, France and Germany rank first and second, with 7,370 and 4,418 active trial sites, respectively.i
“Our strategy has always been to increase the capacity and capabilities of our clinical trial services network, and with the acquisition of Bellwyck Pharma Services earlier this year, we are taking the next step to enhance our capabilities at our new Berlin facility to support the growing clinical trial market in Europe and beyond,” said Salim Haffar, chief executive officer, PCI Pharma Services. “This investment will provide clients with global clinical trial solutions for their life-changing medicines, ensuring continuity of patient supply to match growing market demands.”
About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pci.com or follow us on Twitter at @PCI_Social.
___________________
i ClinicalTrials.gov Web site. Advanced Search of Trial Status Active, not recruiting; Recruiting; Enrolling by invitation. Bethesda (MD): National Library of Medicine (US). Available: https://clinicaltrials.gov/ct2/results/map?recrs=adf&map=. Accessed 2020 July 27.
